KalVista Pharmaceuticals Inc’s recent filing unveils that its CHIEF EXECUTIVE OFFICER Palleiko Benjamin L unloaded Company’s shares for reported $89622.0 on Sep 09 ’24. In the deal valued at $12.19 per share,7,352 shares were sold. As a result of this transaction, Palleiko Benjamin L now holds 250,800 shares worth roughly $2.33 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Audhya Paul K. sold 2,135 shares, generating $26,474 in total proceeds. Upon selling the shares at $12.40, the CHIEF MEDICAL OFFICER now owns 83,745 shares.
Before that, Yea Christopher sold 1,916 shares. KalVista Pharmaceuticals Inc shares valued at $23,758 were divested by the CHIEF DEVELOPMENT OFFICER at a price of $12.40 per share. As a result of the transaction, Yea Christopher now holds 85,676 shares, worth roughly $0.8 million.
H.C. Wainwright initiated its KalVista Pharmaceuticals Inc [KALV] rating to a Buy in a research note published on June 15, 2020; the price target was $30. A number of analysts have revised their coverage, including SVB Leerink’s analysts, who began to cover the stock in late July with a ‘”an Outperform”‘ rating. Needham began covering KALV with “Buy” recommendation on March 20, 2019. Jefferies started covering the stock on October 30, 2018. It rated KALV as “a Buy”.
Price Performance Review of KALV
On Monday, KalVista Pharmaceuticals Inc [NASDAQ:KALV] saw its stock fall -2.00% to $9.30. Over the last five days, the stock has lost -16.14%. KalVista Pharmaceuticals Inc shares have fallen nearly -24.08% since the year began. Nevertheless, the stocks have risen 22.21% over the past one year. While a 52-week high of $16.88 was reached on 02/01/24, a 52-week low of $7.39 was recorded on 11/18/24. SMA at 50 days reached $11.14, while 200 days put it at $12.24.
Levels Of Support And Resistance For KALV Stock
The 24-hour chart illustrates a support level at 8.84, which if violated will result in even more drops to 8.39. On the upside, there is a resistance level at 9.66. A further resistance level may holdings at 10.03. The Relative Strength Index (RSI) on the 14-day chart is 32.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.59%. Stochastics %K at 6.43% indicates the stock is a buying.
How much short interest is there in KalVista Pharmaceuticals Inc?
A steep rise in short interest was recorded in KalVista Pharmaceuticals Inc stocks on 2024-10-31, growing by 0.36 million shares to a total of 6.87 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 6.51 million shares. There was a rise of 5.31%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 21, 2018 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating .
